RT Journal Article
SR Electronic
T1 Genome-wide Screen of Otosclerosis in Population Biobanks: 18 Loci and Shared Heritability with Skeletal Structure
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.15.20227868
DO 10.1101/2020.11.15.20227868
A1 Rämö, Joel T.
A1 Kiiskinen, Tuomo
A1 Karjalainen, Juha
A1 Krebs, Kristi
A1 Kurki, Mitja
A1 Havulinna, Aki S.
A1 Hämäläinen, Eija
A1 Häppölä, Paavo
A1 Hautakangas, Heidi
A1 ,
A1 Karczewski, Konrad J.
A1 Kanai, Masahiro
A1 Mägi, Reedik
A1 Palta, Priit
A1 Esko, Tõnu
A1 Metspalu, Andres
A1 Pirinen, Matti
A1 Ripatti, Samuli
A1 Milani, Lili
A1 Mäkitie, Antti
A1 Daly, Mark J.
A1 Palotie, Aarno
YR 2020
UL http://medrxiv.org/content/early/2020/11/16/2020.11.15.20227868.abstract
AB Otosclerosis is one of the most common causes of conductive hearing loss, affecting 0.3% of the population. It typically presents in adulthood and half of the patients have a positive family history. The pathophysiology of otosclerosis is poorly understood and treatment options are limited. A previous genome-wide association study (GWAS) identified a single association locus in an intronic region of RELN. Here, we report a meta-analysis of GWAS studies of otosclerosis in three population-based biobanks comprising 2,413 cases and 762,382 controls. We identify 15 novel risk loci (p < 5*10−8) and replicate the regions of RELN and two previously reported candidate genes (TGFB1 and MEPE). Implicated genes in many loci are essential for bone remodelling or mineralization. Otosclerosis is genetically correlated with height and fracture risk, and the association loci overlap with severe skeletal disorders. Our results highlight TGFβ1 signalling for follow-up mechanistic studies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe FinnGen project is funded by two grants from Business Finland, a public organization for innovation funding and trade, travel and investment promotion in Finland directed by the Finnish Ministry of Employment and the Economy (HUS 4685/31/2016 and UH 4386/31/2016) and twelve industry partners (https://www.finngen.fi/en/partners). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. The core funding for the Estonian Biobank at the EGCUT is provided by the Estonian Government through the budgets of the Ministry of Social Affairs, the Ministry of Economics and Communications and the Ministry of Education and Research. UKBB was established by the Wellcome Trust medical charity, Medical Research Council, Department of Health, Scottish Government and the Northwest Regional Development Agency. It has also had funding from the Welsh Government, British Heart Foundation, Cancer Research UK and Diabetes UK. UKBB is supported by the National Health Service (NHS).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Review Board of the Hospital District of Helsinki and Uusimaa approved the FinnGen study protocol no. HUS/990/2017. The FinnGen preparatory project is approved by THL, approval number THL/2031/6.02.00/2017, amendments THL/341/6.02.00/2018, THL/2222/6.02.00/2018 and THL/283/6.02.00/2019. The Estonian Biobank (EstBB) study protocol was approved by the Research Ethics Committee of the University of Tartu (Approval number 288/ M-18) . The UKBB Ethics and Governance Framework can be found at: https://www.ukbiobank.ac.uk/wp-content/uploads/2011/05/EGF20082.pdf?phpMyAdmin=trmKQlYdjjnQIgJ%2CfAzikMhEnx6. The Research Ethics Committee reference for UK Biobank is 11/NW/0382.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFinnGen results are subjected to one year embargo and, after that, can be made available to the larger scientific community. Data are released twice a year. For more information, see: https://www.finngen.fi/en/access_results. Genotype and phenotype data are available from the Estonian Biobank (https:// genomics.ut.ee/en/biobank.ee/data-access) upon request. Data from the UK Biobank (UKBB) are made available for approved researchers undertaking health research in the public good. Genomic analyses in the UKBB have been conducted and publicly reported by the Pan UKBB team under proposal number 31063. More information can be found at: https://pan.ukbb.broadinstitute.org and https://registry.opendata.aws/broad-pan-ukb/. https://www.finngen.fi/en/access_results https://www.ukbiobank.ac.uk/scientists-3/genetic-data/